10 Italian life sciences startups wrap U.S. program in Boston

Ten Italian biotech, pharma and healthtech startups are finishing a four-week U.S. residency in Boston on Nov. 13 after three weeks in San Diego. The cohort is pitching cancer therapies, AI healthcare tools and sustainable biomaterials as it looks to meet investors, researchers and potential U.S. partners.

Why it matters: - The program is designed to help Italian startups break into the U.S. life sciences market. - The cohort is meeting researchers, investors and industry partners in two major biotech hubs: San Diego and Boston. - The startups span drug discovery, cancer therapies, digital health and circular-economy biotech, showing where Italian innovation is gaining traction.

What happened: - Ten Italian startups in the Biotech & Pharma cohort of the Italian Trade Agency’s Global Startup Program are completing a four-week U.S. residency. - The residency began with an online training phase from Sept. 28 to Oct. 9. - The group spent three weeks in San Diego and moved to Boston for the final week, which runs through Nov. 13. - The Boston finale includes a Demo Day on Nov. 12. - The program is coordinated by the Italian Trade Agency’s Los Angeles office with the Consulate General of Italy in Los Angeles and Elpis Labs.

The details: - In San Diego, the startups visited BioLabs in the Torrey Pines biotech cluster, UC San Diego and the Salk Institute. - The cohort also met with life sciences investors and industry experts, including representatives of Avalon Ventures. - The startups presented to the local investment and innovation community at a first Demo Day on Nov. 5. - In Boston, the program includes visits to LabCentral in Kendall Square and the Longwood Medical Area. - The Boston schedule also includes meetings with investors and potential industry partners. - The cohort is exploring FDA regulatory pathways, intellectual property, fundraising and U.S. commercialization strategies. - The seventh edition of the Global Startup Program includes six industry-specific cohorts across international innovation hubs. - The initiative aims to strengthen the technical, operational and financial capabilities of participating startups.

Between the lines: - The startup lineup shows how life sciences investment is widening beyond classic therapeutics to include data, workflow and privacy infrastructure. - The mix of cancer drugs, AI tools and biomaterials suggests the Italian ecosystem is trying to compete on both clinical innovation and sustainable manufacturing. - The Boston stop matters because East Coast biotech networks can open doors to academic medical centers, big pharma and later-stage investors.

What's next: - The 10 startups will pitch again at Boston Final Demo Day on Nov. 12. - The cohort will leave the U.S. residency after Nov. 13. - The program is intended to support future international expansion through mentoring, business development and networking.

The bottom line: - Italy is using a structured U.S. biotech roadshow to turn promising startups into companies ready for American partners, capital and commercialization.

The startups: - BrightMol Biotech has built a platform that identifies and validates promising drug molecules directly in living cells. - Kiran Biotech has developed a patented platform designed to retain therapeutic agents locally within tissues, including radiopharmaceuticals and antibodies. - Thera65 is developing a therapy aimed at overcoming drug resistance in certain solid tumors by selectively degrading a tumor-specific protein. - Nemira makes digital tools for communication and coordination among families, caregivers and healthcare professionals caring for older adults, with an initial focus on dementia care and privacy-focused AI features. - Ninacare uses AI to automate recruitment and human resources management for hospitals and care facilities. - QubiTale offers a system that lets hospitals use patient data for research while safeguarding privacy. - V-Apps.cloud provides software that combines quality management, safety, training and regulatory compliance for highly regulated industries, including pharmaceuticals and medical devices. - Alma Serum develops dissolvable cosmetic membranes made from keratin nanofibers without water or preservatives. - AlphaFood makes food and protein products using cricket flour and also develops vertical farming systems plus monitoring, traceability and standardized production software. - Blueat, developed by Mariscadoras, turns invasive blue crabs into food products and uses processing byproducts to create sustainable biomaterials. - The Global Startup Program is supported by ART-ER, Le Village by Crédit Agricole, Fintech District, Italian Angels for Growth, InnovUp, Intesa Sanpaolo, Intesa Sanpaolo Innovation Center, Invitalia, Italian Tech Alliance, UniCredit Start Lab and Zest.